Form Type:  8-K
Filing Date:  5/20/2014 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.01 (0.42%)  
Trade Time: 
Jul 22  
Market Cap: 
Trade SIGA now with 

© 2016  
Description of Business
We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX(TM), also known as Tecovirimat or ST-246®, an orally administered antiviral drug that targets orthopoxviruses. While TPOXX(TM) is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being delivered to the Strategic Stockpile under Project BioShield. BARDA Contract - TPOXX(TM), also known as Tecovirimat or ST-246® On May 13, 2011, SIGA signed the BARDA Contract, pursuant to which SIGA agreed to deliver two million courses of TPOXX(TM) to the Strategic Stockpile. The BARDA Contract is worth approximately $470 million, including $409.8 million for the manufacture and delivery of 1.7 million courses of TPOXX(TM) and $60 million of potential reimbursements related to development and supportive activities (the "Base Contract").
Register and access this filing in:     
  FORM 8-K
      Item 5.07. Submission of Matters to a Vote of Security Holders.